RIEMS, Germany, June 2, 2015 /PRNewswire/ --

- The international specialty pharmaceutical company RIEMSER Pharma GmbH announces a change within its management.

The Chairman of the RIEMSER management board, Priv.-Doz. Dr. med. Kai Deusch, who moved from the advisory board to the management board in January 2014, has left the management board as scheduled on May 31^st, 2015, and returned to the company's advisory board.

The shareholders, advisory board and employees wish to thank Dr. Deusch for his outstanding achievements and successful cooperation.

With effect from June 1^st, 2015, Konstantin von Alvensleben (57) has been appointed Chairman of the RIEMSER management board. As the Managing Director of Schwarz Pharma France, England and Germany, Mr. von Alvensleben has successfully shaped the development of Schwarz Pharma within these markets, especially in the areas of Business Development and In-licensing as well as Marketing and Sales. Following the takeover of Schwarz Pharma by UCB, he has, as Managing Director of UCB in Germany and since 2009 Managing as Director of Takeda, gained extensive experience of both the national and international pharmaceutical business.

"I look forward to using my experience to support RIEMSER in reaching its growth targets and, together with Beatrice von Buchwaldt, who has been in office as Managing Director since 2011, to continuing the company's successful international strategy for expansion with the assistance of our shareholder ARDIAN", said Konstantin von Alvensleben.  

About RIEMSER Pharma GmbH 

RIEMSER Pharma GmbH is a growing European and globally active specialty pharmaceuticals company, which markets, sells and distributes medicinal products for human use in selected therapeutic areas with high unmet medical needs. As part of its strategic growth plan, RIEMSER is currently expanding its market position in European key markets, focusing on accelerating growth in selected areas with high medical needs. RIEMSER has a strong product pipeline and generates lasting value by way of strategic product purchasing and company acquisition coupled with sophisticated life cycle management. RIEMSER has established itself as a modern European platform for the marketing and sales of specialty pharmaceuticals and is an ideal partner for innovative pharmaceutical companies entering new markets for their specialty pharmaceutical products, or intending to extend the life cycles and profitability of their products.

As a responsible company in the pharmaceutical industry, RIEMSER contributes to various medical networks. Among others, these include the association Arzneimittel und Kooperation im Gesundheitswesen (Medicinal Products and Cooperation in the Health Sector), the Bundesverband der Pharmazeutischen Industrie (German Pharmaceutical Industry Association) and the Deutsche Krebsgesellschaft (German Cancer Society).

ABOUT ARDIAN    

Ardian, founded in 1996 and led by Dominique Senequier, is an independent investment company with assets of US$50bn managed or advised in Europe, North America and Asia. The company, which is majority-owned by its employees, keeps entrepreneurship at its heart and delivers investment performance to its global investors while fuelling growth in economies across the world. Ardian's investment process embodies three values: excellence, loyalty and entrepreneurship.

Ardian maintains a truly global network, with more than 350 employees working through ten offices in Paris, London, New York, Beijing, Frankfurt, Jersey, Luxembourg, Milan, Singapore and Zurich. The company offers its 355 investors a diversified choice of funds covering the full range of asset classes, including Fund of Funds (primary, early secondary and secondary), Direct Funds including Infrastructure, Expansion, Mid Cap Buyout, Ardian Growth, Co-Investment and Private Debt.

Press Contact
RIEMSER Pharma GmbH
Claudia Kerber
Head of Communication
Tel.: +49-30-338427-477
E‐Mail: kerber@RIEMSER.com
Website: http://www.RIEMSER.com

SOURCE Riemser Pharma GmbH